Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | PKM | P14618 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.43 |
| ▸ | P2RX2 | Q9UBL9 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 5/20 | 0.43 |
| ▸ | NPC1 | O15118 | 4/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1268291 | 0.93 | L3MBTL1 (0.49) | L3MBTL1KMT2APKMSMN1; SMN2ALOX15 | |
| SCHEMBL1269351 | 0.90 | KMT2A (0.47) | L3MBTL1KMT2ASMN1; SMN2ALOX15P2RX3 | |
| SCHEMBL1269236 | 0.78 | KMT2A (0.48) | L3MBTL1KMT2ASMN1; SMN2ALOX15MAPK1 | |
| SCHEMBL1269332 | 0.77 | RAB9A (0.52) | L3MBTL1KMT2ASMN1; SMN2ALOX15MAPK1 | |
| SCHEMBL1268276 | 0.75 | KMT2A (0.46) | L3MBTL1KMT2ASMN1; SMN2ALOX15MAPK1 | |
| SCHEMBL1268364 | 0.73 | RAB9A (0.47) | L3MBTL1KMT2ASMN1; SMN2ALOX15MAPK1 | |
| SCHEMBL1268302 | 0.73 | KMT2A (0.47) | L3MBTL1KMT2APKMSMN1; SMN2ALOX15 | |
| SCHEMBL1269285 | 0.72 | KMT2A (0.49) | L3MBTL1KMT2APKMSMN1; SMN2ALOX15 | |
| SCHEMBL1269375 | 0.71 | KMT2A (0.47) | L3MBTL1KMT2ASMN1; SMN2ALOX15MAPK1 | |
| SCHEMBL1269618 | 0.71 | KMT2A (0.47) | L3MBTL1KMT2APKMSMN1; SMN2ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110039893-A1 | GSK-3BETA INHIBITOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-02-17 | — | — | US | claimed |
| US-20110039893-A1 | GSK-3BETA INHIBITOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039893-A1 | GSK-3BETA INHIBITOR | GSK3B, GSK3A, GSKIP | L3MBTL1 1593/4885KMT2A 575/4885PKM 647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.